UBS Group’s Cadrenal Therapeutics CVKD Stock Holding History

UBS Group’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.33K	Buy	5,861 +4,749	+427%	+$8.62K	﹤0.01%	9427
2026 Q2	$3.71K	Buy	1,112 +1,109	+36,967%	+$5.27K	﹤0.01%	9153
2026 Q1	$15	Sell	3 -1,041	-100%	-$7.3K	﹤0.01%	10310
2025 Q4	$7.08K	Buy	1,044 +1,009	+2,883%	+$11.4K	﹤0.01%	8478
2025 Q3	$484	Sell	35 -291	-89%	-$3.6K	﹤0.01%	9651
2025 Q2	$3.93K	Sell	326 -8,119	-96%	-$121K	﹤0.01%	9308
2025 Q1	$149K	Buy	8,445 +6,273	+289%	+$115K	﹤0.01%	6749
2024 Q4	$31.5K	Buy	+2,172	New	+$31.4K	﹤0.01%	7570
2023 Q4	–	Sell	-9	Closed	-$92	–	9383
2023 Q3	$92	Buy	+9	New	+$128	﹤0.01%	8907
2023 Q2	–	Sell	-15	Closed	-$330	–	8758
2023 Q1	$324	Buy	+15	New	+$457	﹤0.01%	9074

Other funds holding CVKD

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group's CVKD Position: Q3 2026 in Review

UBS Group increased its Cadrenal Therapeutics (CVKD) stake by 427% in Q3 2026, buying an estimated $8.62K and bringing the position to 5,861 shares worth $6.33K. The position accounts for ﹤0.01% of the portfolio, ranked #9427.

UBS Group first reported a position in CVKD in Q1 2023 and has held it in 10 quarters since. The position peaked at $149K in Q1 2025. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

UBS Group held 5,861 shares of Cadrenal Therapeutics worth $6.33K as of Q3 2026.
UBS Group bought 4,749 Cadrenal Therapeutics shares in Q3 2026, an estimated $8.62K.
Cadrenal Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9427 holding.
UBS Group first reported a position in Cadrenal Therapeutics in Q1 2023 and has held it in 10 quarters since.
UBS Group's Cadrenal Therapeutics position peaked at $149K in Q1 2025.
23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.